Stansky Michael P
Known title: DirectorCIK: 0001424204
Stansky Michael P's purchase track record
Stansky Michael P has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/15/2026 | TLSI | $1.52M | +96.6% | pending | — |
| 2/23/2026 | TLSI | $1.48M | -35.5% | +2.4% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TLSI | ▲ Buy | Open Market | 410,000 | $1.0M | 5/15/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 200,000 | $500K | 5/15/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 23,501 | $0 | 5/14/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 20,089 | $0 | 5/14/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 243,900 | $1000K | 2/23/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 117,198 | $481K | 2/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance
TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.